2026 autoimmune car-t and immune reset clinical landscape covering endpoints, sponsors, phases, geographies, readouts, assets and development white space.

2026 next-generation obesity therapeutics clinical landscape covering endpoints, sponsors, phases, geographies, readouts, assets and development white space.

Sanofi 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Gilead Sciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Merck & Co. 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Novartis 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Roche 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Novo Nordisk 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Eli Lilly 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Bristol Myers Squibb 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Pfizer 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

AstraZeneca 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.